National Pension Service Cuts Stock Position in Amgen Inc. $AMGN

National Pension Service lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,146,313 shares of the medical research company’s stock after selling 17,376 shares during the period. National Pension Service’s holdings in Amgen were worth $320,062,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Abel Hall LLC bought a new position in shares of Amgen in the first quarter worth approximately $232,000. Apollon Financial LLC grew its holdings in shares of Amgen by 5.4% during the first quarter. Apollon Financial LLC now owns 995 shares of the medical research company’s stock valued at $310,000 after buying an additional 51 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Amgen by 48.9% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,254 shares of the medical research company’s stock valued at $391,000 after acquiring an additional 412 shares in the last quarter. Finally, Hager Investment Management Services LLC increased its position in shares of Amgen by 2.7% during the first quarter. Hager Investment Management Services LLC now owns 5,079 shares of the medical research company’s stock valued at $1,582,000 after acquiring an additional 133 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $338.45 on Wednesday. The firm has a market capitalization of $182.25 billion, a P/E ratio of 27.67, a PEG ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen Inc. has a one year low of $253.30 and a one year high of $338.55. The business has a fifty day moving average of $291.69 and a 200 day moving average of $289.36.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. UBS Group lowered their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Cantor Fitzgerald boosted their price target on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group dropped their price objective on Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Citigroup boosted their target price on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $307.94.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.